Drug Information

Drug (ID: DG00800) and It's Reported Resistant Information

• Name: Prochlorperazine
• Synonyms: Prochlorperazine; 58-38-8; Prochlorperazin; Prochlorpromazine; Chlormeprazine; Chlorperazine; Procloperazine; Capazine; Prochlorpemazine; Compazine; Proclorperazine; Meterazin; Meterazine; Stemetil; Tementil; Kronocin; Emelent; Nipodal; Temetid; Prochlorpermazine; Novamin; Proclorperazina; Bayer A 173; Prochlorperazine maleate; Prochloroperazine; Prochlorperazinum; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; Vertigon; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; SKF 4657; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 6140 RP; RP 6140; UNII-YHP6YLT61T; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-; Buccastem; CHLOPERAZINE; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; MLS000028600; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; 10H-Phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Compro; YHP6YLT61T; Prochlorperazine Base; SMR000058705; Prochlorperazine mesylate; CHEBI:8435; 2-chloro-10-(3-(4-methylpiperazin-1-yl)propyl)-10h-phenothiazine; Compazine Suppositories; Phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-; Prochlorperazinum [INN-Latin]; Proclorperazina [INN-Spanish]; Proazine; MLS001148133; Compro (TN); NSC17478; NSC167375; HSDB 3171; CAS-84-02-6; Compazine (*Maleate*); SMR000653454; EINECS 200-379-4; Chloropernazine; Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-; Prochlorperazine (JAN/USP/INN); 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; Prochlorperazine [USP:INN:BAN:JAN]; Eskatrol (Salt/Mix); Spectrum_000840; Opera_ID_244; Prestwick0_000399; Prestwick1_000399; Prestwick2_000399; Prestwick3_000399; Spectrum2_001297; Spectrum3_000881; Spectrum4_000972; Spectrum5_001339; Lopac-P-9178; CHEMBL728; Probes1_000265; Probes2_000307; Lopac0_001034; SCHEMBL18429; BSPBio_000617; BSPBio_002394; KBioGR_001343; KBioGR_002304; KBioSS_001320; KBioSS_002306; cid_91499; MLS006011830; DivK1c_000413; SPBio_001333; SPBio_002538; BPBio1_000679; GTPL7279; DTXSID7023514; BDBM78434; KBio1_000413; KBio2_001320; KBio2_002304; KBio2_003888; KBio2_004872; KBio2_006456; KBio2_007440; KBio3_001762; KBio3_002784; cMAP_000013; NINDS_000413; HMS2231P21; STL371212; ZINC19796018; AKOS003600762; CCG-205112; DB00433; RP-6140; SDCCGSBI-0051005.P005; IDI1_000413; MRF-0000068; NCGC00015856-01; NCGC00015856-02; NCGC00015856-03; NCGC00015856-04; NCGC00015856-05; NCGC00015856-06; NCGC00015856-07; NCGC00015856-16; NCGC00023036-03; NCI60_022783; P77; SBI-0051005.P004; 6140 R.P.; DB-053199; AB00053532; FT-0603243; C07403; C16030; D00493; AB00053532_29; AB00053532_30; 058P388; A831861; L001030; Q2359690; BRD-K19352500-070-02-5; BRD-K19352500-070-05-8; BRD-K19352500-332-03-7; SR-01000000260-11; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)-propyl)-phenothiazine; N-(.gamma.-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; Phenothiazine, 2-chloro-10-[3-(1-methyl-4-piperazinyl)propyl]-; 2-Chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine #; 2-chloranyl-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine;ethane-1,2-disulfonic acid; 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine;ethane-1,2-disulfonic acid; 2-chloro-10-[3-(4-methylpiperazino)propyl]phenothiazine;ethane-1,2-disulfonic acid
• Indication:
  In total 1 Indication(s)
  Nausea [ICD-11: MD90]; Approved; [1]
• Target: Dopamine D2 receptor (D2R); DRD2_HUMAN; [1]
• Formula: C20H24ClN3S
• IsoSMILES: CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
• InChI: 1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
• InChIKey: WIKYUJGCLQQFNW-UHFFFAOYSA-N
• PubChem CID: 4917
• ChEBI ID: CHEBI:8435
• TTD Drug ID: D0B2UZ
• VARIDT ID: DR00592
• INTEDE ID: DR1345
• DrugBank ID: DB00433

Type(s) of Resistant Mechanism of This Drug

  IDUE: Irregularity in Drug Uptake and Drug Efflux

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Brain cancer [ICD-11: 2A00]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: Multidrug resistance protein 1 (ABCB1) [1]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Glioblastoma [ICD-11: 2A00.02]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell invasion; Inhibition; hsa05200
• Cell Pathway Regulation: Cell migration; Inhibition; hsa04670
• In Vitro Model: SHI-1 cells; Bone marrow; Homo sapiens (Human); CVCL_2191
• Experiment for Molecule Alteration: Western blotting analysis; RNA-sequencing analysis
• Experiment for Drug Resistance: Wound healing assay;Transwell assay
• Mechanism Description: Prochlorperazine may modulate the expression levels of multidrug resistance proteins (they decreased ABCB1 and increased ABCG2 expression), E-cadherin, alpha-tubulin and integrins, and could impair the migration and invasion of U-87 MG cells.

Key Molecule: ATP-binding cassette sub-family G2 (ABCG2) [1]

• Molecule Alteration: Expression; Up-regulation
• Sensitive Disease: Glioblastoma [ICD-11: 2A00.02]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell invasion; Inhibition; hsa05200
• Cell Pathway Regulation: Cell migration; Inhibition; hsa04670
• In Vitro Model: SHI-1 cells; Bone marrow; Homo sapiens (Human); CVCL_2191
• Experiment for Molecule Alteration: Western blotting analysis; RNA-sequencing analysis
• Experiment for Drug Resistance: Wound healing assay;Transwell assay
• Mechanism Description: Prochlorperazine may modulate the expression levels of multidrug resistance proteins (they decreased ABCB1 and increased ABCG2 expression), E-cadherin, alpha-tubulin and integrins, and could impair the migration and invasion of U-87 MG cells.

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Integrin alpha-3 (ITA3) [1]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Glioblastoma [ICD-11: 2A00.02]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell invasion; Inhibition; hsa05200
• Cell Pathway Regulation: Cell migration; Inhibition; hsa04670
• In Vitro Model: SHI-1 cells; Bone marrow; Homo sapiens (Human); CVCL_2191
• Experiment for Molecule Alteration: Western blotting analysis; RNA-sequencing analysis
• Experiment for Drug Resistance: Wound healing assay;Transwell assay
• Mechanism Description: Prochlorperazine may modulate the expression levels of multidrug resistance proteins (they decreased ABCB1 and increased ABCG2 expression), E-cadherin, alpha-tubulin and integrins, and could impair the migration and invasion of U-87 MG cells.

Key Molecule: Integrin beta-1 (ITGB1) [1]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Glioblastoma [ICD-11: 2A00.02]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell invasion; Inhibition; hsa05200
• Cell Pathway Regulation: Cell migration; Inhibition; hsa04670
• In Vitro Model: SHI-1 cells; Bone marrow; Homo sapiens (Human); CVCL_2191
• Experiment for Molecule Alteration: Western blotting analysis; RNA-sequencing analysis
• Experiment for Drug Resistance: Wound healing assay;Transwell assay
• Mechanism Description: Prochlorperazine may modulate the expression levels of multidrug resistance proteins (they decreased ABCB1 and increased ABCG2 expression), E-cadherin, alpha-tubulin and integrins, and could impair the migration and invasion of U-87 MG cells.

References

• Ref 1: Perphenazine and prochlorperazine decrease glioblastoma U-87 MG cell migration and invasion: Analysis of the ABCB1 and ABCG2 transporters, E-cadherin, Alpha-tubulin and integrins (Alpha3, Alpha5, and Beta1) levels .Oncol Lett. 2022 Jun;23(6):182. doi: 10.3892/ol.2022.13302. Epub 2022 Apr 15. 10.3892/ol.2022.13302